Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P407: Prospective evaluation of clinical efficacy and safety of golimumab in biologic experienced and naïve patients with moderate to severe ulcerative colitis: experience from a tertiary referral centreECCO '17 Barcelona
Year: 2017
Authors:

Orlandini B., Dragoni G., Bagnoli S., Deiana S., Macrì G., Rogai F.

Careggi, Gastroenterology, Florence, Italy

P408: Long-term efficacy of infliximab in patients with ulcerative colitis – an observational study from a single center in NorwayECCO '17 Barcelona
Year: 2017
Authors:

Lerang F., Henriksen M., Jelsness-Jørgensen L.-P.

Central Hospital of Østfold, Medical, Sarpsborg, Norway

P409: Mesalamine enemas for induction of remission in pediatric ulcerative colitis refractory to oral mesalamine: a prospective cohort studyECCO '17 Barcelona
Year: 2017
Authors:

Levine A.*1, Yerushalmi B.2, Kori M.3, Broide E.4, Mozer-Glassberg Y.5, Shaoul R.6, Kolho K.-L.7, Shteyer E.8, Shamaly H.9, Ledder O.10, Cohen S.11, Peleg S.12, Sarbagili-Shabat C.1, Focht G.10, Shachmon E.10, Boaz M.13, On A.14, Turner D.10

1Paediatric and Gastroenterology and Nutrition Unit, Wolfson Medical Center, Tel Aviv University, Holon, Israel 2Soroka University Medical Center and Faculty of Health Sciences, Ben-Gurion University of the Negev, Beer-Sheva, Israel 3Kaplan Hospital, Rehovot, Israel 4Assaf Harofeh Medical Center, Tel Aviv, Israel 5Schneider's Children Hospital, Peatach Tikva, Israel 6Rambam Medical Center, Haifa, Israel 7Children's Hospital and Helsinki University, Helsinki, Finland 8Hadassah Medical Center, Jerusalem, Israel 9French Hospital, Nazareth Hospital, Israel 10Juliet Keidan Institute of Paediatric Gastroenterology, Shaare Zedek Medical Center, The Hebrew University of Jerusalem, Jerusalem, Israel 11Tel Aviv Medical Center, Tel Aviv University, Tel Aviv, Israel 12Haemek Hospital, Afula, Israel 13Department of Nutrition Sciences, Ariel University; Epidemiology and Research Unit, E. Wolfson Medical Center, Holon, Israel 14Poriah Hospital, Tiberius, Israel and Bar-Ilan University, The faculty of medicine in the Galilee, Sefad, Israel

P410: Vedolizumab is safe and effective for IBD, but has no effect on liver biochemistry in patients with concurrent PSCECCO '17 Barcelona
Year: 2017
Authors:

Christensen B.*1, Micic D.2, Gibson P.R.1, Singh S.3, Bellaguarda E.2, Corsello P.4, Gaetano J.N.5, Kinnucan J.4, Rao V.L.5, Reddy S.2, Yarur A.3, Rubin D.T.5, Pekow J.5

1Alfred Hospital and Monash University, Melbourne, Australia 2Northwestern University Feinberg School of Medicine, Chicago, United States 3Medical College of Wisconsin, Wisconsin, United States 4University of Michigan Health System, Ann Arbor, United States 5University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States

P411: Drug persistence and need for dose intensification to adalimumab therapy; the importance of therapeutic drug monitoring in inflammatory bowel diseasesECCO '17 Barcelona
Year: 2017
Authors:

Kurti Z.*1, Rutka M.2, Vegh Z.1, Gonczi L.1, Farkas K.2, Lovasz B.D.1, Gecse K.B.1, Golovics P.A.1, Szalay B.3, Molnar T.2, Lakatos P.L.1

1Semmelweis University, First Department of Medicine, Budapest, Hungary 2University of Szeged, First Department of Internal Medicine, Szeged, Hungary 3Semmelweis University, Department of Laboratory Medicine, Budapest, Hungary

P412: The Sicilian network of biological therapy in inflammatory bowel disease: preliminary data on efficacyECCO '17 Barcelona
Year: 2017
Authors:

Orlando A.1, Macaluso F.S.*1, Fries W.2, Privitera A.C.3, Cappello M.4, Siringo S.5, Inserra G.6, Magnano A.7, Di Mitri R.8, Belluardo N.9, Scarpulla G.10, Magrì G.11, Trovatello N.12, Carroccio A.13, Genova S.14, Calandruccio G.15, Vassallo R.16, Romano C.17, Pellegrino S.17, Citrano M.18, Accomando S.19, Ventimiglia M.1, Renna S.1, Orlando R.1, Rizzuto G.1, Vinci E.1, Cottone M.1

1Division of Internal Medicine, “Villa Sofia-Cervello” Hospital, Palermo, Italy 2Inflammatory bowel disease Unit, A.O.U. Policlinico “G. Martino”, Messina, Italy 3IBD Unit, A.O. “Cannizzaro”, Catania, Italy 4Gastroenterology and Hepatology Unit, A.O.U. Policlinico “G. Giaccone”, Palermo, Italy 5Gastroenterology Unit, A.R.N.A.S. “Garibaldi”, Catania, Italy 6Internal Medicine Unit, A.O.U. Policlinico “Vittorio Emanuele”, Catania, Italy 7Gastroenterology Unit, A.O.U. Policlinico “Vittorio Emanuele”, Catania, Italy 8Gastroenterology and endoscopy Unit, A.R.N.A.S. “Civico Di Cristina Benfratelli”, Palermo, Italy 9Gastroenterology Unit, A.O. “Guzzardi”, Vittoria, Italy 10Gastroenterology Unit, A.O.O.R. “S. Elia- M. Raimondi”, Caltanissetta, Italy 11Gastroenterology Unit, A.O. “Santa Marta e S. Venera”, Acireale, Italy 12Surgery Unit, A.O. “Umberto I”, Siracusa, Italy 13Internal Medicine Unit, A.O. “Giovanni Paolo II”, Sciacca, Italy 14Gastroenterology and Endoscopy Unit, A.O. “S. Antonio Abate”, Trapani, Italy 15Gastroenterology Unit, A.O.O.R. “Papardo Piemonte”, Messina, Italy 16Gastroenterology and Endoscopy Unit, A.O. “Buccheri La Ferla Fatebenefratelli”, Palermo, Italy 17Pediatric Gastroenterology Unit, A.O.U. Policlinico “G. Martino”, Messina, Italy 18Pediatric Unit, A.O.O.R. “Villa Sofia-Cervello”, Palermo, Italy 19Pediatric Unit, A.O.U. Policlinico “G. Giaccone”, Palermo, Italy

P413: Exclusive enteral nutrition provides an effective bridge to safer interval elective surgery for Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Heerasing N.*1, Thompson B.1, Hendy P.1, Heap G.1,2, Walker G.1,2, Bethune R.1, Calvert C.1, Kennedy N.1,2, Ahmad T.1,2, Goodhand J.1,2

1Royal Devon & Exeter NHS Foundation Trust, Gastroenterology, Exeter, United Kingdom 2University of Exeter, Exeter, United Kingdom

P414: Vedolizumab in Pediatric inflammatory bowel diseases: a retrospective multi-center experience from the paediatric IBD Porto group of ESPGHANECCO '17 Barcelona
Year: 2017
Authors:

Ledder O.*1, de Meij T.2, Martín de Carpi J.3, Richmond L.4, Cohen S.5, Bronsky J.6, Shaoul R.7, Levine A.8, Escher J.9, deRidder L.9, Assa A.10, Ruemmele F.11, Shah N.12, Wolters V.13, Rodrigues A.14, Uhlig H.14, Urlep D.15, Posovsky C.16, Kolho K.17, Turner D.1

1Shaare Zedek Medical Center, Pediatric Gastroenterology, Jerusalem, Israel 2VU Medical Centre, Amsterdam, Netherlands 3Hospital Sant Joan de Deu, Barcelona, Spain 4Royal Hospital for Sick Children, Glasgow, United Kingdom 5Dana Medical Center, Tel Aviv, Israel 6University Hospital Motol, Prague, Czech Republic 7Rambam Medical Center, Haifa, Israel 8Wolfson Medical Center, Holon, Israel 9Erasmus Medical Center, Rotterdam, Netherlands 10Schneider Medical Center, Petach Tikva, Israel 11Hopital Necker Enfants Malades, Paris, France 12Great Ormond Street Hospital, London, United Kingdom 13University Medical Center Utrecht, Utrecht, Netherlands 14Oxford University Hospital, Oxford, United Kingdom 15Ljubljana University Medical Center, Ljubljana, Slovenia 16University Medical Center, Ulm, Germany 17Helsinki University Central Hospital, Helsinki, Finland

P415: Trends in narcotic and corticosteroid prescriptions in patients with inflammatory bowel disease in the United States ambulatory care setting from 2003 to 2011ECCO '17 Barcelona
Year: 2017
Authors:

Narula N.*1, Borges L.2, Steinhart A.H.3, Colombel J.-F.4

1McMaster University, Gastroenterology, Hamilton, Canada 2Brigham and Women's Hospital, Boston, United States 3Mount Sinai Hospital, Toronto, Canada 4Mount Sinai Hospital, Gastroenterology, New York, United States

P416: Real world data on the effectiveness and safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis: the Edinburgh experienceECCO '17 Barcelona
Year: 2017
Authors:

Plevris N., Manship T.A., Deekae A., Jones G.R., Noble C.L., Satsangi J., Shand A.G., Arnott I.D., Lees C.W.

NHS Lothian - Western General Hospital, Department of Gastroenterology, Edinburgh, United Kingdom

P417: Non-invasive assessment of liver fibrosis by transient elastography and AST to ALT ratio in patients with Crohn's disease treated with methotrexateECCO '17 Barcelona
Year: 2017
Authors:

Peixoto A., Silva M., Morais R., Liberal R., Gonçalves R., Lopes S., Macedo G.

Centro Hospitalar São João, Gastroenterology, Porto, Portugal

P418: Pharmacodynamic biomarkers demonstrate dose-dependent pharmacological activity of the IL-22Fc fusion protein UTR1147A in healthy volunteers in a phase 1a clinical trialECCO '17 Barcelona
Year: 2017
Authors:

Lekkerkerker A., Harder B., Kulkarni P., Zhao R., Choi M., Noyes A., Polihrom A., Fillos D., Rae J., Danilenko D., Stefanich E., Herman A., Lu T.

Genentech, Research and Early Development, South San Francisco, United States

P419: Concentrations of anti-TNF agents in non-inflamed intestinal tissue are associated with the long-term outcome of patients with Crohn's diseaseECCO '17 Barcelona
Year: 2017
Authors:

Yoshihara T., Shinzaki S., Kawai S., Iwatani S., Yamaguchi T., Araki M., Hiyama S., Inoue T., Hayashi Y., Watabe K., Iijima H., Takehara T.

Osaka university, Gastroenterology and Hepatology, Suita, Osaka, Japan

P420: Anti-TNF for post-operative prevention in Crohn's disease: the detection of anti-drug antibodies at time of surgery is associated with an increased risk of endoscopic recurrenceECCO '17 Barcelona
Year: 2017
Authors:

Auzolle C.*1, Houze P.2, Tran-Minh M.-L.1, Nancey S.3, Buisson A.4, Fumery M.5, Pariente B.6, Djenidi F.1, Marteau P.7, Bouhnik Y.8, Seksik P.7, Allez M.7

1Saint-Louis Hospital, Department of Gastroenterology, Paris, France 2Saint-Louis Hospital, Department of Biochemistry, Paris, France 3Lyon-Sud Hospital, Hospices Civils de Lyon, Department of Gastroenterology, Pierre-Benite, France 4CHU Estaing, Department of Gastroenterology, Clermont-Ferrand, France 5CHU Amiens, Department of Gastroenterology, Amiens, France 6Claude Huriez Hospital, Department of Gastroenterology, Lille, France 7Saint-Antoine Hospital, Department of Gastroenterology, Paris, France 8Beaujon Hospital, Department of Gastroenterology, Clichy, France

P421: Comparative efficacy and impact on patient-reported outcomes of pharmacological therapies for moderate to severe ulcerative colitis: a systematic review and network meta-analysisECCO '17 Barcelona
Year: 2017
Authors:

Paschos P.1,2, Katsoula A.2, Giouleme O.*2, Tsapas A.1,3

1Aristotle University, Clinical Research and Evidence-Based Medicine Unit, Second Medical Department, Thessaloniki, Greece 2Aristotle University, Second Propedeutic Medical Department, Thessaloniki, Greece 3University of Oxford, Harris Manchester College, Oxford, United Kingdom

P422: Patient-near Infliximab trough-level testing by a novel quantitative rapid test; the Quantum Blue Infliximab assayECCO '17 Barcelona
Year: 2017
Authors:

Roseth A.*1, Lindsjô I.2, Malmstrøm G.-H.3

1Lovisenberg Hospital, Medicine, Oslo, Norway 2Lovisenberg Diakonale Hospital, Deparment Of Gastroenterology, Oslo, Norway 3UngerVetlesen Institute, Oslo, Norway

P423: Early improvement in quality of life in patients with luminal Crohn's disease treated with adalimumab. Data from RAPIDA trialECCO '17 Barcelona
Year: 2017
Authors:

Casellas F.*1, Barreiro-de Acosta M.2, Esteve M.3, Castro-Laria L.4, Vicente R.5, Ceballos D.6, Echarri A.7, Martín-Arranz M.D.8, Busquets D.9, Llaό J.10, Navarro-Llavat M.11, Huguet J.M.12, Argüelles-Arias F.4, Boudet J.M.5, Rodríguez-San Pedro L.13, Díaz G.13, Casado R.13, Marín I.14

1Hospital Universitari Vall Hebron, Barcelona, Spain, Barcelona, Spain 2Hospital Clínico Universitario de Santiago, Santiago de Compostela, Spain 3Hospital Universitari Mutua Terrassa, Barcelona, Spain 4Hospitales Universitarios Virgen Macarena-Rocío, Sevilla, Spain 5Hospital Universitario Miguel Servet, Zaragoza, Spain 6Dr. Negrin University Hospital, Las Palmas, Spain 7Complejo Hospitalario Universitario de Ferrol, Ferrol, Spain 8Hospital Universitario la Paz, Madrid, Spain 9Hospital Universitari Dr. Josep Trueta, Girona, Spain 10Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain 11Hospital de Sant Joan Despí Moisès Broggi, Barcelona, Spain 12Hospital General Universitario de Valencia, Valencia, Spain 13Abbvie, Madrid, Spain 14Hospital Universitario Gregorio Marañόn, Madrid, Spain

P424: Association between infliximab trough levels, clinical remission, mucosal healing and quality of life in patients with inflammatory bowel disease on maintenance therapyECCO '17 Barcelona
Year: 2017
Authors:

Parra R.S., Feitosa M.R., Féres O., Rocha J.J.R.d.

University of São Paulo, Department of Surgery and Anatomy, Ribeirão Preto, Brazil

P425: Biosimilar infliximab in real-life Crohn's disease treatment in anti-TNF-alpha naïve and non-naïve patients in comparison to biologic originator: a comparative observational cohort studyECCO '17 Barcelona
Year: 2017
Authors:

Kaniewska M.*1, Moniuszko A.1, Maciejewska K.1, Rydzewska G.1,2

1Central Clinical Hospital of Ministry of Internal Affairs and Administration, Warsaw, Poland, Gastroenterology, Warsaw, Poland 2Faculty of Medicine and Health Science, UJK, Kielce, Poland, Kielce, Poland

P426: Supra-therapeutic infliximab levels are not associated with a higher risk of infection in IBD patientsECCO '17 Barcelona
Year: 2017
Authors:

Greener T.*1, Kabakchiev B.2, Silverberg M.3

1Mount Sinai Hospital, Department of Gastroenterology, Toronto, Canada 2Mount Sinai Hospital, Joseph and Wolf Lebovic Health Complex Zane Cohen Centre for, Toronto, Canada 3University of Toronto, Gastroenterology Division, Toronto, Canada